RECIST and Cancer Response Evaluation

These flashcards cover essential vocabulary concerning RECIST and cancer response evaluation, aiding in understanding key concepts for effective study.

RECIST

Response Evaluation Criteria In Solid Tumors, a standard approach to measure solid tumors and evaluate treatment response.

Target Lesions

Lesions chosen for measurement and tracking in cancer evaluation, typically limited to 1-5 lesions.

• preferably the biggest lesions

• maximum of two per organ

Non-target Lesions

Lesions that cannot be precisely measured but can be followed for changes (e.g. ascites, pleural effusion).

Sum of Longest Diameters (SLD)

Calculation of the total longest diameters of the target lesions, used to assess tumor response.

Complete Response (CR)

Total disappearance of all target lesions and any new lesions.

Partial Response (PR)

At least a 30% decrease in the SLD from baseline.

Progressive Disease (PD)

At least a 20% increase in the SLD from the lowest point or Nadir.

Stable Disease (SD)

No significant change in SLD and neither PR nor PD.

Baseline Study

Initial assessment of the patient's tumor size and characteristics before treatment starts.

Follow-up Evaluation

Assessment conducted after treatment to monitor changes in tumor lesions.